首页> 外文期刊>World Journal of Gastroenterology >Peroxisome proliferator-activated receptor γ ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats
【24h】

Peroxisome proliferator-activated receptor γ ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats

机译:过氧化物酶体增殖物激活受体γ配体抑制二乙基亚硝胺诱导的大鼠肝癌发生

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: Peroxisome proliferator-activated receptor γ (PPARγ) is known to regulate growth arrest and terminal differentiation of adipocytes and is used clinically as a new class of antidiabetic drugs. Recently, several studies have reported that treatment of cancer cells with PPARγ ligands could induce cell differentiation and apoptosis, suggesting a potential application as chemopreventive agents against carcinogenesis. In the present study, 3 different kinds of PPARγ ligands were subjected to the experiments to confirm their suppressive effects on liver carcinogenesis. METHODS: Three PPARγ ligands, pioglitazone (Pio) (200 ppm), rosiglitazone (Rosi) (200 ppm), and troglitazone (Tro) (1 000 ppm) were investigated on the induction of the placental form of rat glutathione S-transferase (rGST P) positive foci, a precancerous lesion of the liver,and liver cancer formation using a diethylnitrosamine-induced liver cancer model in Wistar rats, and dose dependency of a PPARγ ligand was also examined. RESULTS: PPARγ ligands reduced the formation of rGST P-positive foci by diethylnitrosamine and induction of liver cancers was also markedly suppressed by a continuous feeding of Pio at 200 ppm. CONCLUSION: PPARγ ligands are potential chemopreventive agents for liver carcinogenesis.
机译:目的:过氧化物酶体增殖物激活受体γ(PPARγ)可以调节脂肪细胞的生长停滞和终末分化,在临床上被用作一类新型的抗糖尿病药物。最近,一些研究报告称用PPARγ配体处理癌细胞可以诱导细胞分化和凋亡,这表明它可能作为化学预防剂用于抗癌作用。在本研究中,对3种不同的PPARγ配体进行了实验,以证实它们对肝癌发生的抑制作用。方法:研究了三种PPARγ配体,吡格列酮(Pio)(200 ppm),罗格列酮(Rosi)(200 ppm)和曲格列酮(Tro)(1000 ppm)诱导大鼠谷胱甘肽S-转移酶的胎盘形式(在Wistar大鼠中使用二乙基亚硝胺诱导的肝癌模型研究了rGST P)阳性灶,肝癌前病变和肝癌形成以及PPARγ配体的剂量依赖性。结果:PPARγ配体减少了由二乙基亚硝胺形成的rGST P阳性灶的形成,并且通过连续饲喂200 ppm的Pio也显着抑制了肝癌的诱导。结论:PPARγ配体是潜在的肝癌化学预防剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号